New designer drugs (synthetic cannabinoids and synthetic cathinones): Review of literature

Current Pharmaceutical Design

Volumn 20, Issue 25, 2014, Pages 4106-4111

  Cottencin, Olivier ^a,b   Rolland, Benjamin ^a,b   Karila, Laurent ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

Legal highs; Recreative drugs; Synthetic cannabinoids; Synthetic cathinones

Indexed keywords

4' METHYLMETHCATHINONE; CANNABINOID; CATHINONE; DESIGNER DRUG; METHYLEN DIOXY PYROVALERONE; METHYLONE; UNCLASSIFIED DRUG; ALKALOID;

ARTICLE; CATHA EDULIS; DRUG ABUSE; DRUG COST; DRUG LEGISLATION; INTERNET; NONHUMAN; PRIORITY JOURNAL; ADDICTION; CHEMISTRY; DRUG DESIGN; HUMAN; SYNTHESIS;

ALKALOIDS; CANNABINOIDS; DRUG DESIGN; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 84904062662     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990622     Document Type: Article

References (56)

1. EMCDDA 2013 European Drug Report (Trends and develop ments). Available on http: //www.emcdda.europa.eu/attachements.cfm/att_213154_EN_TDA T13001ENN1.pdf
2. EMCDDA-Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA (New drugs in Europe, 2012).
3. Zawilska JB. "Legal highs - new players in the old drama. Curr Drug Abuse Rev 2011; 4: 122-130.
4. Johnson LA, Johnson RL, Alfonzo C. Spice: a legal marijuana equivalent. Mil Med 2011; 176: 718-720.
5. Karila L, Reynaud M. GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test Anal 2011; 3: 552-559.
6. Wells DL, Ott CA. The new marijuana. Ann Pharmacother 2011; 45: 414-417.
7. Griffiths P, Lopez D, Sedefov R, et al. Khat use and monitoring drug use in Europe: the current situation and issues for the future. J Ethnopharmacol 2010; 132(3): 578-583.
8. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012; 8(1): 33-42.
9. Drugscope 2013. Available on http: //www.drugscope.org.uk/resources/drugsearch/drugsearchpages/mephedrone.htm
10. EMCDDA: 2010. EMCDDA and Europol step up information collection on mephedrone. http://www.emcdda.europa.eu/publications/drugnet/online/2010/69/article3 http://www.emcdda.europa.eu/
11. Carhart-Harris RL, King LA, Nutt DJ. A web-based survey on mephedrone. Drug Alcohol Depend 2011; 118(1): 19-22.
12. Winstock A, Mitcheson L, Deluca P, et al. Mephedrone, new kid for the chop? Addiction 2011; 106: 154-161.
13. Debruyne D, Courné MA, Le Boisselier R, et al. Mephedrone: a designer drug of recent use in France. Thérapie 2010; 65: 519-524.
14. EMCDDA. European Monitoring Center for Drugs and Drug Abuse: Annual report 2011: The state of the drug problem in Europe. http: //www.emcdda.europa.eu/publications/annual-report/2011
15. Karila L, Reynaud M: Mephedrone: A designer drug legally available on the Web. Presse Med 2010; 39(7-8): 834-835.
16. Petit A, Karila L, Sananes M, Lejoyeux M. Mephedrone: A new synthetic drug. Presse Med 2013 10. pii: S0755-4982(13)00539-3.
17. Wood DM, Davies S, Puchnarewicz M, et al. Recreational Use of Mephedrone (4-Methylmethcathinone, 4-MMC) with Associated Sympathomimetic Toxicity. J Med Toxicol 2010; 6(3): 327-330.
18. Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 2011; 28(4): 280-282.
19. Gibbons S, Zloh M. An analysis of the 'legal high' mephedrone. Bioorg Med Chem Lett 2010; 20(14): 4135-4139.
20. Dickson AJ, Vorce SP, Levine B, Past MR. Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephe-drone) and heroin. J Anal Toxicol 2010; 34(3): 162-168.
21. TREND. Phénomènes émergents liés aux drogues en 2008. Rapport Metz. Saint-Denis: OFDT; 2009.
22. Regan L, Mitchelson M, Macdonald C. Mephedrone toxicity in a Scottish emergency department. Emerg Med J 2011; 28(12): 1055-1058.
23. Meyer MR, Maurer HH. Metabolism of designer drugs of abuse: an updated review. Curr Drug Metab 2010; 11(5): 468-482.
24. EMCDDA: EMCDDA-Europol 2009 Annual Report on the im plementation of Erowid: 2013 http: //www.erowid.org/chemicals/methylone/methylone_info1.shtml
25. Meyer MR, Wilhelm J, Peters FT, Maurer HH. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrome-try. Anal Bioanal Chem 2010; 397(3): 1225-1233.
26. Shimizu E, Watanabe H, Kojima T, et al. Combined intoxication with methylone and 5-MeO-MIPT. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(1): 288-291.
27. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011; 49: 705-719
28. Karila L, Petit A, Cottencin O, Coscas S, Reynaud M. Synthetic drugs: the new low-cost landscape of drugs. Rev Prat 2012; 62(5): 664-666.
29. Coppola M, Mondola R. 3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 2012; 208: 12-15
30. Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol In-terv 2011; 11: 36-51.
31. Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39(2): 234-243.
32. Hudson S, Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal 2011; 3: 466-478.
33. Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA. Designer drugs: a medicinal chemistry perspective. Ann N Y Acad Sci 2012; 1248: 18-38.
34. Fattore L, Fratta W. Beyond THC: The New Generation of Can-nabinoid Designer Drugs. Front Behav Neurosci 2011; 5: 60.
35. American Association of Poison Control Centre (AAPCC). Fake marijuana spurs more than 4,500 calls to US Poison Centers. http: //www.aapcc.org/dnn/Portals/0/prrel/updatedk2-may112011.pdf 2011
36. Muller H, Sperling W, Köhrmann M, Huttner HB, Kornhuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010; 118: 309-321.
37. Every-Palmer S. Warning: legal synthetic cannabinoid-receptor agonists such as JWH018 may precipitate psychosis in vulnerable individuals. Addiction 2010; 105: 1859-1860.
38. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 2011; 117: 152-157.
39. Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 2011; 168: 1119.
40. Castellanos D, Singh S, Thornton G, Avila M, Moreno A. Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 2011; 49: 347-349.
41. Schneir AB, Cullen J, Ly BT. "Spice" girls: synthetic cannabinoid intoxication. J Emerg Med 2011; 40: 269-296.
42. Forrester MB, Kleinschmidt K, Schwarz E, Young A.Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis 2011; 30(4): 351-358.
43. Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 2013; 44(2): 360-366.
44. Simmons J, Cookman L, Kang C, Skinner C. Three cases of "spice" exposure. Clin Toxicol 2011; 49: 431-433.
45. Simmons JR, Skinner CG, Williams J, Kang CS, Schwartz MD, Wills BK. Intoxication from smoking "Spice". Ann Emerg Med 2011b; 57: 187-188.
46. Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol 2011; 49: 760-764.
47. Schneir AB, Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 2012; 8: 62-64.
48. Young AC, Schwarz E, Medina G, et al. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 2012; 30(7): 1320.e5-1320.e7.
49. Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011; 128: 1622-1627.
50. Akirav I. The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus. Front Behav Neurosci 2011; 5: 34-39
51. Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand 2011; 124: 250-261.
52. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Span-agel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "Spice Gold". Dtsch Artzebl Int 2009; 106: 464-467.
53. Hu X, Primack BA, Barnett TE, Cook RL. College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy 2011; 6: 16-19.
54. Cameron K, Kolanos R, Verkariya R, De Felice L, Glennon RA. Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of bath salts, produce opposite effects at the human dopamine transporter. Psychopharmacology (Berl) 2013; 227(3): 493-499.
55. Blum K, Foster Olive M, Wang KK, et al. Hypothesizing that designer drugs containing cathinones (bath salts) have profound neuro-inflammatory effects and dangerous neurotoxic response following human consumption. Med Hypotheses 2013 8. doi: 10.1016/j.mehy.2013.06.007. [Epub ahead of print]
56. Kamat AS, Aliashkevich AF, Denton JR, Fitzjohn TP. Headache after substance abuse: a diagnostic dilemma. J Clin Neurosci 2012; 19(3): 464-466.